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Abstract. Poly(ADP-ribose) (PAR) has been identi-
fied as a DNA damage-inducible cell death signal
upstream of apoptosis-inducing factor (AIF). PAR
causes the translocation of AIF from mitochondria to
the nucleus and triggers cell death. In living cells, PAR
molecules are subject to dynamic changes pending on
internal and external stress factors. Using RNA
interference (RNAi), we determined the roles of
poly(ADP-ribose) polymerases-1 and -2 (PARP-1,
PARP-2) and poly(ADP-ribose) glycohydrolase
(PARG), the key enzymes configuring PAR mole-
cules, in cell death induced by an alkylating agent. We
found that PARP-1, but not PARP-2 and PARG,
contributed to alkylation-induced cell death. Like-
wise, AIF translocation was only affected by PARP-1.
PARP-1 seems to play a major role configuring PAR
as a death signal involving AIF translocation regard-
less of the death pathway involved.
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Introduction
Poly(ADP-ribose) polymerases-1 and -2 (PARP-1,
PARP-2) and poly(ADP-ribose) glycohydrolase
(PARG) are important components of the cellular
DNA damage surveillance network [1, 2]. PARP-1
and PARP-2 play a dual role as DNA damage sensors
and signal transducers to downstream endpoints such
asDNA repair and cell death pathways [3–7]. PARP-1
and PARP-2 bind rapidly to DNA strand breaks,
become activated, and covalently modify themselves
as well as other nuclear proteins. Large amounts of
long and branched negatively charged poly (ADP-
ribose) (PAR) molecules are synthesized at the
expense of NAD+ that is cleaved into ADP-ribose
and nicotinamide. The constitutive intracellular levels
of PAR are usually very low in unchallenged cells
[8–10], but in response toDNAdamaging agents, they
increase 10–500-fold due to the activation of PARP-1
andPARP-2 [1, 2, 4, 11–13]. Poly(ADP-ribose) (PAR)
accumulation is transient because PAR is rapidly
degraded by PARG [14, 15]. PARG differentially
regulates PAR turnover by cleaving polymers both
endoglycosidically and exoglycosidically, generating
shorter polymers and free ADP-ribose, respectively
[16]. In mammals, PARG is encoded by a single gene;
however, it is expressed as multiple isoforms, which
arise from alternative splicing (99, 102 and 111 kDa, in
human cells) [17]. PARG has a high specific activity
and acts in concert with PARPs to maintain intra-
cellular PAR levels at low concentrations under
homeostatic conditions. The importance of this coor-
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dinated mechanism is underlined by the finding that
failure to degrade PAR in PARG-knockout mice
causes embryonic lethality [18].
Recently, Dawson and collaborators [19–21] demon-
strated that PAR may act as a cell death signal
upstream of apoptosis-inducing factor (AIF). AIF is a
mitochondrial intermembrane flavoprotein that
translocates to the nucleus in response to specific
death signals [22]. In the nucleus, AIF triggers
chromatin condensation as well as large-scale
(~50 kb) DNA fragmentation.
In the present study, we used RNA interference
(RNAi) in human cells to selectively down-regulate
PARP-1, PARP-2 and PARG, either separately or
simultaneously, to determine their individual contri-
butions to modulating PAR as a cell death signal.
PARP activation was induced by the alkylating agent
N-methyl-N’-nitro-N’-nitrosoguanidine (MNNG),
that acts by formation ofDNAadducts at nucleobases,
resulting in induction of cell death through production
of DNA strand breaks [23]. We used low concentra-
tions (50 mM) of MNNG to induce cell death, which
produced substantial but not lethal damage to cells.
Apart from silencing, we monitored the effects on cell
death, PAR formation, AIF translocation and caspase
activation. Our results suggest that of the two tested
PARP enzymes, PARP-1 is the major contributor to
the PAR signal inducing cell death and AIF trans-
location, but not caspase activation. Interestingly,
RNAi-mediated silencing of PARGdid not affectAIF
translocation induced by MNNG, although it led to a
significant accumulation of PAR.
Materials and methods
Cell culture.All media and supplements used for cell
culturing were obtained from GIBCO (Invitrogen,
Basel, Switzerland). Human cervical carcinoma cells
(HeLa S3) and mouse embryonic fibroblasts (MEFs)
were cultured at 378C in a water-saturated 5% CO2/
95% air atmosphere, in Dulbeccos modified Eagles
medium (DMEM) containing 4500 mg/l glucose and
supplemented with 10% (v/v) fetal bovine serum
(FBS) and antibiotics (complete DMEM).
Synthesis of small interfering RNAs and transfection.
Small interferingRNAs (siRNAs)were synthesized in
vitro from oligonucleotide templates (Microsynth,
Balgach, Switzerland) using an siRNA construction
kit (Ambion, Austin, TX, USA), according to manu-
facturers instructions. Purified siRNAs were dis-
solved in water at a concentration of 20 mM and
stored at –808C until use. As targets for RNAi,
21-nucleotide sequences in the human coding region
of PARP-1, PARP-2 and PARG cDNA were chosen
following the instructions of the Ambion webpage
based on the siRNA design guidelines first described
by Tuschl and colleagues [24]. siRNA sequences
shown in Fig. 1 (top) resulted in maximal silencing
efficacies as compared to several tested siRNAs. A
scrambled version of siRNAwas also synthesized and
used as a negative control.
Cells were grown to 50–70% confluence in 6-well
plates and transfected with siRNAs at a final concen-
tration of 80 nM in 1000 ml OptiMEM, using siPORT
Amine (Ambion) as the transfection reagent. After
incubation for 4 h at 378C, 2 ml/well completeDMEM
was added and cells were allowed to grow for the times
indicated. For time course experiments, cells were
subcultured after 72 h and allowed to grow for
indicated times. In cell growth experiments, silenced
cells were harvested by trypsinization, seeded in six-
well plates and transfected again using exactly the
conditions described above. In this way, several
rounds of subculturing, transfection and growth were
repeated on the same cell stocks. Cells were collected
at various times after transfection to determine
PARP-1 and PARP-2 protein and mRNA levels as
well as PARG activity.
Cell extracts for PARG activity assay. Cells grown in
24-well plates were collected in 30 mM Tris/HCl
(pH 7.5) buffer, containing 0.5 M NaCl, 20% (v/v)
glycerol and 1% Triton X-100 (0.5 ml/well), and
incubated for 30 min on ice. Whole-cell extracts
were obtained after centrifugation at 10 000 g for
10 min at 48C. Supernatants were divided into aliquots
and stored at 808C until use.
Synthesis of PARP-bound [32P]PAR and PAR deg-
radation assay. PARP-bound [32P]PAR was synthe-
sized in vitro, by incubation of 1.5 UPARP-1 (Biomol)
in 100 mM Tris/HCl (pH 8.0) buffer, containing
400 mM [32P]NAD+ (0.1 mCi/nmol, Perkin Elmer),
10 mM MgCl2, 2 mM dithiothreitol (DTT), 0.5 mg
nicked calf thymusDNA, 10% (v/v) ethanol and 10%
glycerol, in a final volume of 27 ml. After 30 min of
incubation at 308C, the reaction was stopped by
precipitation with 0.7 vol. of propan-2-ol in the
presence of 0.3 M sodium acetate (pH 5.2) [25]. The
pellet containing PARP-bound [32P]PAR was collect-
ed by centrifugation, washed with ethanol, air-dried
and finally resuspended in 50 mM Tris/HCl (pH 7.4),
containing 14 mM 2-mercaptoethanol, 0.5 mM phe-
nylmethylsulphonyl fluoride (PMSF) and 20% glyc-
erol. This sample was subsequently used as a substrate
to determine enzymatic PAR degradation in cell
extracts.
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PARG activity was determined in cell extracts by an
enzymatic assay using PARP-bound [32P]PAR as a
substrate and 2-ml cell extracts as the enzyme source.
Incubation was in 50 mM potassium phosphate buffer
(pH 7.4), containing 50 mM KCl, 10 mM 2-mercap-
toethanol and 100 mg/ml BSA [25] in a final volume of
24 ml. Reactions were started by adding 200 pmol
protein-bound [32P]PAR and allowed to proceed for
10 min at 378C. Then, an equal volume of ice-cold
40% (w/v) trichloroacetic acid was added and, after
centrifugation at 13 000 g for 15 min, the radioactivity
in the supernatant was measured in a liquid-scintilla-
tion counter (Beckmann). PARG activity in siRNA-
transfected cells was expressed as percentage of the
values detected for control cells, transfected with
scrambled siRNA. Purified calf thymus PARG and
1 mM ADP (hydroxymethyl) pyrrolidinediol (ADP-
HPD; Calbiochem, San Diego, CA, USA), a specific
PARG inhibitor, were used as controls.
Western blot analyses. Cells were washed with ice-
cold PBS and then harvested directly in Laemmli
buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 2% 2-
mercaptoethanol, 8% glycerol, 0.0025% bromphenol
blue), sonicated and incubated for 1 min at 958C.
Soluble proteins were collected in the supernatants
after centrifugation, separated by electrophoresis on
SDS-polyacrylamide gels and finally electroblotted on
PVDF membranes (Bio-Rad, Hercules, CA, USA).
Blots were probed with monoclonal anti-PARP-1
(Alexis, Lausen, Switzerland; C2–10; 1:5000), poly-
clonal anti-PARP-1 p85 fragment (Promega, Madi-
son, WI, USA; 1:500), polyclonal anti-AIF (Serotec,
Raleigh, NC, USA; 1:500), monoclonal anti-bax
(Calbiochem; 1:2000), monoclonal anti-bcl-2 (Santa
Cruz, c-2; 1:250), monoclonal anti-PARP-2 (Alexis;
4G8; 1:50), monoclonal anti-proliferating-cell nuclear
antigen (PCNA; BDBiosciences, San Jose, CA,USA;
1:5000), monoclonal anti-p53 (Oncogene, ab-1;
1:5000), polyclonal anti-cleaved caspase-7 (Cell Sig-
naling Technology, Boston, MA, USA; 1:1000), poly-
clonal anti-cleaved caspase-9 (Cell Signaling Technol-
ogy; 1:1000), monoclonal anti-glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH; Ambion, Austin,
TX, USA; 1:80 000), monoclonal anti-manganese
superoxide dismutase (MnSOD; BD Biosciences;
Figure 1. Specific knockdown of
poly(ADP-ribose) polymerase
(PARP)-1, PARP-2 and poly(-
ADP-ribose) glycohydrolase
(PARG) by RNA interference
(RNAi). The table shows select-
ed genes for siRNA-mediated
RNA interference. (A) Western
blot analysis of PARP-1 protein
levels in HeLa cells transfected
with control and PARP-1-specif-
ic siRNAat indicated time points
after transfection. The amount of
loadedproteinwas normalized to
a-tubulin. (B) PARP-1 detection
by immunofluorescence of
siRNA transfected HeLa cells
after 24 h. DAPI staining of cel-
lular DNA is also shown. (C)
Relative fold-changes of PARP-2
expression after RNAi of PARP-
2 as detected by real time RT-
PCR at indicated time points and
Western blot analysis 48 h after
siRNA. Error bars indicatemean
 SD in % of control of three
independent experiments. (D)
PARG activity was analyzed as
described in the Materials and
methods section at different time
points after transfection.All data
were normalized to protein con-
tent and the values obtained with
control cells were set at 100%.
Results represent means  SD
for at least six independent ex-
periments.
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1:1000), monoclonal anti-topoisomerase I (Topo-I,
BD Biosciences; 1:5000) and monoclonal anti-a-
tubulin antibodies (Sigma, Buchs, Switzerland;
1:5000), in succession. Immunodetection was per-
formed by ECL (Pierce, Rockford, IL, USA; ECL
detection kit). Images were acquired by exposure to
autoradiographic films.
PCR analyses. cDNAwas produced from control and
siRNA-transfected cells without prior isolation of
RNA using the Cells-to-cDNA II kit (Ambion) under
the conditions described in themanufacturersmanual.
These samples were then used as templates for
GAPDH, PARP-1 and PARP-2 amplification in quan-
titative real-time PCR, with specifically designed
primers (Assay-on-demandGeneExpression products,
Applied Biosystems, Foster City, CA, USA), in a
reaction mixture including TaqMan Universal PCR
Master Mix (Applied Biosystems). Real-time PCR
analyses were carried out on an ABI PRISM 7700
cycler, at the default setting program (958C, 15 s; 608C,
1 min; 40 cycles). For the quantification of changes in
gene expression, the DDCt method was used to
calculate the relative fold changes normalized against
GAPDH.
Immunofluorescence analyses. For PARP-1, at 24 h
after transfection with either PARP-1-specific or
scrambled siRNA, cells were subcultured and grown
on cover slips for 24 h. The medium was removed and
cells were washed with ice-cold PBS and immediately
fixed in 3% paraformaldehyde for 15 min at room
temperature followed by incubation in 100 mM gly-
cine in PBS for 2 min at room temperature. After
washing with PBS, cells were incubated with 3%milk,
0.05% Tween 20, in PBS (PBS-TM), for 1 h at 378C,
and then exposed to a monoclonal antibody against
PARP-1 (c2–10; Alexis) diluted 1:200 in PBS-TM for
1 h at 378C. For AIF/PAR, at 72 h after siRNA
transfection, cells were subcultured and grown on
cover slips for 24 h. Treatmentwith 50 mMMNNGwas
performed for 30 min in case of PAR, and for 6 h in
case of AIF detection. After MNNG incubation, the
drug containing medium was removed and cells were
washed with ice-cold PBS and immediately fixed in
methanol/acetone (1:1) for 20 min at 208C. After
washing with PBS, cells were incubated with 3% (w/v)
milk in PBS (PBS-M) for 1 h at 378Cand then exposed
to either a polyclonal antibody against PAR (LP96–
10; Alexis) diluted 1:200 in PBS-M or a polyclonal
antibody against AIF (Serotec) diluted 1:200 in PBS-
M for 1 h at 378C. Finally, samples were incubated for
1 h at room temperature with an Alexa Fluor 488-
conjugated secondary antibody (Molecular Probes,
Invitrogen, Basel, Switzerland) diluted 1:200. DNA
was stained either with 4, 6-diamidino-2-phenylin-
dole (DAPI) or with Hoechst 33258 dissolved in PBS
at 10 mg/ml or 0.2 mg/ml, respectively. Cover slips were
mounted on glass slides with 0.1% Mowiol (Calbio-
chem) and examined with a fluorescence microscope
(Nikon) connected to a digital camera (Kappa,
Gleichen, Germany).
Cell growth and viability assay. Cell growth and
viability were assessed by a dye reduction bioassay
(Alamar Blue assay; Serotec). Briefly, 72 h after
transfection, confluent cells were harvested by trypsi-
nization, resuspended in complete DMEM and seed-
ed into 6-well (cell growth assay) or 96-well (cytotox-
icity analyses) plates at a density of 250 000 or
20 000 cells/well, respectively. To determine drug-
induced cytotoxicity, MNNG was dissolved in
DMSO at 2.0 M and diluted in complete DMEM to
final dilutions ranging from 10 to 500 mM just before
use. After attachment of cells to the bottom of the
plates, complete DMEM containing MNNG was
added to exponentially growing cells in 96-well plates.
After 20-h incubation at 378C, the medium was
replaced with complete DMEM containing 10% (v/
v) Alamar blue. Metabolic reduction of the vital dye
was assessed by spectrofluorimetry: fluorescence was
monitored at 530 nm excitation wavelength and
590 nm emission wavelength, using an LS 55 lumines-
cence spectrometer (Perkin-Elmer, Wellesley, MA,
USA). In cytotoxicity experiments, the broad spec-
trum caspase inhibitors benzyloxycarbonyl-Val-Ala-
Asp-(O-Me)fluoromethyl ketone (Z-VAD.fmk;
100 mM; Calbiochem) and Gln-Val-Asp(non-O-me-
thylated)-OPh (Q-VD-OPh; 20 mM; Calbiochem)
were added to the culture medium as indicated for
the entire treatment time. Twelve-fold determinations
of each sample were performed on a single experi-
ment. Based on the results shown in Figure S2, 50 mM
concentrations of MNNGwere used in all subsequent
experiments.
Measurement of the ADP/ATP ratio. The ADP/
ATP ratio was determined using the ApoGlow kit
(LumiTech Ltd. , Nottingham, UK); the assay is
based on bioluminescence measurement of the
adenylate nucleotides and allows the assessment
of the mode of cell death [26] . Cells were grown in
white clear-bottom 96-well plates and treated ex-
actly as indicated above; at different times after
treatment, cells were lysed in nucleotide-releasing
reagent and processed for ATP and ADP determi-
nation as described in the kits instruction manual.
Luminescence was measured using the MLXmicro-
titer plate luminometer (Dynex Technologies,
Chantilly, VA, USA). Quintuplicate determinations
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of each sample were performed on a single silencing
experiment.
PAR analysis. Cells were transfected with the indi-
cated siRNAs and treated with 50 mMMNNG for 1 h.
For control experiments, cells were grown in the
presence of the PARP-inhibitor 3-aminobenzamide
(3-AB, 3 mM) for 1 h before and during the entire
subsequent treatment time. Then, adherent cells were
washed in situ with PBS, overlaid with 100 mM Tris/
HCl (pH 8.0) containing 10 mM MgCl2, 2 mM DTT,
20 mg/ml digitonin and 1 mCi [32P]NAD+ and incubat-
ed for 15 min at 378C. At the end of the incubation
time, citric acid was added to a final concentration of
25 mM; cells were harvested, transferred on to ice and
immediately precipitated by addition of trichloro-
acetic acid (20%, final concentration). Trichloroacetic
acid pellets were collected by centrifugation, washed
three times with ethanol and once with diethyl ether.
At this step, incorporation of [32P]NAD+was assessed
by measuring the radioactivity in a liquid-scintillation
counter (Beckmann). Finally, the pellet was resus-
pended in TE buffer (10 mM Tris/HCl, pH 8.0, and
1 mM EDTA) containing 0.5 mg/ml proteinase K
(Sigma). After overnight incubation at 378C, the pH
was raised to 12.0 by Tris/NaOH addition; samples
were further incubated for 1 h at 608C and finally
subjected to high-resolution PAGE and autoradiog-
raphy. Polymer size distributions were analyzed by
densitometric scanning and quantification of auto-
radiographic band intensities (ImageQuant 3.15;
Molecular Dynamics/GE Healthcare).
Annexin V staining. Either untreated or MNNG-
treated cells were double-stained for annexin V and
propidium iodide (PI) using the Annexin-V-Fluos
Staining Kit (Roche, Basel, Switzerland) according to
themanufacturers protocol. Briefly, following 8 h and
24 h of drug treatment (50 mM MNNG), total cells
grown in 6-well plates were washed with PBS and
typsinized. Subsequently, annexin V-fluorescein and
PI were added to the cells, which were incubated for
15 min at room temperature in the dark. After
incubation, cells were washed once with PBS, resus-
pended and examined by fluorescence microscopy
analysis. From each sample, 1200 cells (8 h) and 1900
cells (24 h) were analyzed for annexin V and PI
staining in two independent experiments. Total cell
numbers were determined by cell counting using a
Neubauer counting chamber.
Cellular subfractionation. Cellular subfractionation
was performed as described [27]. Briefly, HeLa cells
were harvested and washed twice with 1 mM Tris-
HCl (pH 7.0), 0.13 M NaCl, 5 mM KCl, 7.5 mM
MgCl2. After incubation in 3.5 mM Tris-HCl
(pH 7.8), 3 mM NaCl, 0.5 mM MgCl2 for 5 min,
cells were mechanically broken. The homogenate
was immediately mixed with one-ninth of the cell
volume of 0.35 M Tris-HCl (pH 7.8), 0.2 M NaCl,
50 mM MgCl2, and spun for 3 min at 1600 g to pellet
unbroken cells, debris and nuclei. The pellet was
harvested directly in Laemmli buffer and the super-
natant was recentrifuged under the same conditions.
The final supernatant was spun at 13 000 g for 1 min
and the resulting mitochondrial pellet was washed
once with 35 mM Tris-HCl (pH 7.8), 20 mM NaCl,
5 mM MgCl2, then twice with 10 mM Tris-HCl
(pH 7.4), 1 mM EDTA, 0.32 M sucrose and finally
resuspended in Laemmli buffer. The entire purifica-
tion process was performed at 48C and a protease
inhibitor cocktail (CompleteTM, EDTA-free; Boeh-
ringer, Ingelheim, Germany) was added to all Tris
buffers at the recommended concentration just
before use. Whole mitochondria fraction and one-
tenth of the nuclear fraction were used for SDS-
PAGE and Western blot analysis. For quantification,
band intensities were measured by scanning densi-
tometry using the ImageQuant software (Molecular
Dynamics/GE Healthcare) and data were normal-
ized to mitochondrial (MnSOD) and nuclear (Topo-
I) markers, respectively.
Other methods. Protein concentration was deter-
mined either by the method of Lowry et al. [28] or
using the Bradford protein assay reagent (Bio-Rad),
with BSA as a standard.
Supplemental material.All supplemental information
(Figures S1–S4) are available on our website www.vet-
pharm.uzh.ch/suppl/.
Results
Knocking-down PARP-1, PARP-2 and PARG gene
expression by RNAi. We used RNAi to selectively
down-regulate PARP-1, PARP-2 and PARG expres-
sion in the human cancer cell line HeLa. From the
coding region of human PARP-1, PARP-2 and PARG
cDNA, 21-nucleotide sequences were selected as
targets for RNAi and the corresponding siRNAs
(Fig. 1, top, describing the names of the selected genes,
their NCBI accession numbers and the regions from
which dsRNAs were derived) were synthesized in
vitro as described under Materials and methods. A
scrambled version of these siRNAs was used as
negative control (siRNA-C). To examine the effect
of siRNAs on the expression of PARP-1, a time-
course analysis of PARP-1 protein expression was
648 O. Cohausz et al. PARPs and PARG in cell death
carried out in whole cell lysates. As shown in Fig. 1A,
transfection of HeLa cells with PARP-1-specific
siRNA reduced PARP-1 protein expression by 16 h,
and remained at low/undetectable levels from 24 to
96 h. Figure 1B shows the effect of PARP-1 silencing
by indirect immunofluorescence. The green nuclear
signal, identified with monoclonal anti-PARP-1 anti-
body, was abolished by 24 h [Fig. 1B (siRNA-P1)],
while it remained unchanged in cells transfected with
control siRNA (siRNA-C). When we established
transient knockdown of PARP-2 gene expression,
quantification by real-time RT-PCR confirmed a
maximal decrease in PARP-2 mRNA levels that
reached values of 16.1% at 24 h after transfection
with siRNA-P2 and a time-dependent recovery to
29.7% (72 h) and 36.2% (144 h), respectively
(Fig. 1C). PARP-2 protein levels were decreased to
15.6% 48 h after RNAi specific for PARP-2 (Fig. 1C).
To determine the silencing efficacy of PARG siRNA
(siRNA-G) on PAR catabolism, PARG activity was
quantified in transfected cells. A time-course experi-
ment of PAR-degrading activity was carried out in
whole-cell lysates. After transfection into HeLa cells,
siRNA-G caused a progressive loss of enzymatic
activity that was maximal after 72 h (847%)
(Fig. 1D).
Generally, the average silencing efficacy of our
experiments was 9010% for PARP-1, 7013.5%
for PARP-2 and 847% for PARG, 72 h after specific
siRNA. In all experiments, a scrambled siRNA was
completely ineffective, as judged by comparison with
non-transfected cells, and hence was taken as the
negative control. In addition, no apoptotic fragmen-
tation of PARP-1 [29] was detected in RNAi experi-
ments, confirming the absence of primary (trans-
fection-related) or secondary (PARP/PARG down-
regulation-related) cytotoxic effects (see below).
Furthermore, PARP as well as PARG silencing did
not cause any morphological changes, growth defects
or cell death, as assessed by light microscopy, cell
counting, viability assays and biochemical analyses of
protein expression (Fig. S1 and data not shown).
Silenced cells retained the ability to attach and
proliferate under routine subculture conditions and
even recurrent transfections on successive subcultures
did not affect the cell growth of silenced HeLa cells
(Fig. S1).
Effect of PARP-1, PARP-2 and PARG silencing on
PAR metabolism. We next examined the effects of
PARP-1, PARP-2 and PARG down-regulation on
PAR synthesis in DNA-damaged cells by immuno-
fluorescence analysis. In the experiment illustrated in
Figure 2A, HeLa cells were subcultured 72 h after
transfection with siRNA and grown on cover slips for
24 h before exposure to the alkylating agent MNNG
(50 mM) for 30 min. As expected, MNNG-induced
polymer synthesis was suppressed by PARP-1 silenc-
ing and by pharmacological inhibition of PARP
activity (3-AB). PARP-2 silencing had no visible
effect on PAR formation, whereas simultaneous
down-regulation of PARP-1 and PARP-2 abrogated
MNNG-induced PAR formation. However, large
amounts of PAR were formed in PARG-siRNA-
transfected cells that clearly exceeded the PAR
formation levels of control cells. Triple silencing
(siRNA-P1, -P2, -G) led to PAR formation compara-
ble to levels seen in control cells.
Given the inherent limitations of immunofluores-
cence microscopy, it is difficult to monitor small
changes in PAR formation. Therefore, we directly
analyzed the PAR molecules synthesized under var-
ious silencing conditions.
ADP-ribose incorporation was low in untreated con-
trol as well as in PARP-1-, PARP-2- and PARG-down-
regulated cells, but markedly stimulated after moder-
ate doses of MNNG (Fig. 2B). As expected, this
increase was reduced in PARP-1, and to a lesser
extent, in PARP-2-down-regulated cells. Simultane-
ous down-regulation of PARP-1 and PARP-2, as well
as pretreatment with the PARP-inhibitor 3-AB,
abrogated MNNG-induced PAR formation. In con-
trast, PARGsilencing led to an increase inPAR.Triple
silencing (siRNA-P1, -P2 and -G) led to PAR for-
mation comparable to control cells, as both PAR
synthesis and PAR degradation were suppressed
within these cells.
We next focused on the size of PAR molecules
synthesized under various silencing conditions
using SDS-PAGE (Fig. 2C, D). Under basal con-
ditions, control as well as PARP-1-, PARP-2- and
PARG-down-regulated cells showed generally low
levels of intracellular PAR. PAR levels of PARP-1-
and PARP-2- ACHTUNGTRENNUNGdown-regulated cells exhibited no
differences in comparison to control cells, apart
from a marginal decrease in polymers of short and
medium length (<20 ADP-ribose units). In con-
trast, a slight increase in short and medium (<20
ADP-ribose units) and particularly long (>20ADP-
ribose units) polymers could be observed in PARG-
silenced cells (Fig. 2C, D). As expected, MNNG-
induced PAR formation of control cells was reduced
in PARP-1-silenced, and to a lesser extent, in
PARP-2-silenced cells. By contrast, an accumula-
tion of PAR was observed in PARG-siRNA-trans-
fected cells, reflecting a reduced degradation of
polymers. Furthermore, the quantification of indi-
vidual PAR molecules showed an increase in
polymers of short, medium and long sizes after
MNNG treatment in PARG-silenced cells
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(Fig. 2D). Taken together, RNAi allows us to
selectively down-regulate the major contributors
to PAR metabolism and thus modulate the PAR
signal leading to cell death [19–21] .
Monitoring alkylation-induced cell death: Effect of
PARPs and PARG silencing. Using fluorescence
microscopy, we analyzed cell numbers, and annexin
V and PI staining (Fig. 3A). Cell death induced by
50 mMMNNG progresses from 55% at 8 h to 80% at
24 h. At 8 h, a marked proportion of cells (13%)
became annexin V positive, indicating apoptotic cell
death. Half of these annexin V-positive cells appeared
to be PI positive at the same time, whereas only a low
proportion of cells was stained exclusively for PI. At
the later time-point (24 h), the proportion of annexin
V-positive cells that was PI positive at the same time
increased, whereas fewer cells appeared to be exclu-
sively annexin V positive. Again, only a low propor-
tion of cells was stained exclusively for PI. Taken
together, our data indicate at both time points that the
majority of cells die by apoptosis (annexinV positive),
whereas only a negligible number of cells undergo
necrosis (exclusively PI positive).
Figure 3B shows the effects of PARP-1, PARP-2 and
PARG silencing on the cytotoxicity of 50 mMMNNG.
PARP-1 silencing increased HeLa cell survival from
134.3% to 275.6%, while PARP-2 and PARG
silencing had no significant effect. Similar findings
were obtained in mouse embryonic fibroblasts show-
Figure 2. Analyses of poly(-
ADP-ribose) (PAR) synthesis in
HeLa cells after RNAi against
PARP-1, PARP-2 and PARG.
(A) Immunofluorescence analy-
sis of PAR levels in HeLa cells
transfected with siRNA or treat-
ed with 3-aminobenzamide (3-
AB) as indicated immediately
after treatment with 50 mM N-
methyl-N-nitro-N-nitrosoguani-
dine (MNNG) for 30 min. (B)De
novo synthesis of PAR after 1 h
of 50 mM MNNG treatment in
HeLa cells. Stressed cells were
made permeable by a mild dig-
itonin shock to allow the uptake
of radiolabeled NAD+ as descri-
bed in Materials and methods.
The average radioactivity incor-
poration of three independent
experiments is shown (* p<0.05,
unpaired t-test). The values are
normalized to untreated control
cells. HeLa cells were transfected
with small interfering RNA
(siRNA) or treated with 3-AB
as indicated. (C) PAR analysis by
PAGE and autoradiography de-
tection after 1-h treatment with
50 mM MNNG as described in
Materials and methods section.
(D) Quantification of (C) was
carried out by scanning densi-
tometry of individual bands with
ImageQuant software (Molecu-
lar Dynamics/GE Healthcare).
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ing that PARP-1 silencing protected against MNNG-
induced cell death, whereas PARG silencing did not
[30]. Simultaneous down-regulation of PARP-1 and
PARP-2 offered no additional cytoprotection inHeLa
cells as compared to PARP-1-silenced cells. Taken
together, our data demonstrate an alkylation-induced
cell death in HeLa cells that can be prevented in part
by PARP-1 silencing.
One of the early hallmarks of cell death is a moderate
increase in the ADP/ATP ratios from 0.1 to 1.0 for
apoptotic cells and a dramatic increase beyond 1.0 in
cells undergoingnecrosis [26, 31]. TheADP/ATPratios
shown in Figure 3C confirmed the healthy status of
untreated HeLa cells, with a value below 0.1. Silencing
of PARP-1, PARP-2 or PARP-1 + PARP-2 did not
raise the ratio above 0.1.However, after treatmentwith
50 mM MNNG, the ADP/ATP ratio increased to a
maximum of 0.750.04 in control cells, indicative of
apoptotic cell death. PARP-1 silencing had a cytopro-
tective effect, while PARP-2 silencing was ineffective.
Likewise, double silencing of PARP-1 and PARP-2was
cytoprotective to MNNG-treated HeLa cells, but no
more than single silencing of PARP-1.
Involvement of caspases in MNNG-induced cell
death. The role of caspase activation in MNNG-
Figure 3. MNNG-induced death
in HeLa cells. (A) HeLa cells
were treated with 50 mMMNNG
for indicated timepoints. Positive
staining for annexin Vand propi-
dium iodide (PI) was assessed by
fluorescencemicroscopy analysis
and expressed as percent of the
untreated control cells. Results
represent the means of two in-
dependent experiments. Total
cell numbers were determined
by cell counting using a Neuba-
uer counting chamber. (B) Ex-
ponentially growing HeLa cells
transfected with siRNAs for 72 h
as indicated were treated with
50 mM MNNG for 24 h. Cell
viabilities were detected by the
Alamar blue assay and expressed
as a percent of the untreated
control cells. Results represent
the means SD for at least three
independent experiments (*
p<0.005, unpaired t-test). (C)
ADP/ATP ratio measurement.
HeLa cells were treated with
MNNG (50 mM) and processed
for luminescence detection of the
adenylate nucleotides after 8 h.
Results are the means  SD for
quadruplicate determinations (*
p<0.0001, unpaired t-test).
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induced cell death was monitored using the broad-
spectrum caspase inhibitors Z-VAD.fmk and Q-VD-
OPh, and by measuring the formation of the typical
cleavage products of PARP-1 and caspases-7 and -9.
MNNG-induced cell death was prevented to 90% by
either of the pan-caspase-inhibitors Z-VAD.fmk and
Q-VD-OPh (Fig. 4A), suggesting a strong involve-
ment of caspases. This was also evident with the
appearance of the PARP-1 cleavage product and
caspases-7 and -9 cleavage fragments (Fig. 4C). None
of the silencing treatments affected the formation of
cleavage products, suggesting that this process is not
dependent on PARPs or PARG. Nevertheless, activa-
tion of caspases-7 and -9 could be completely blocked
with the caspase-inhibitor Q-VD-OPh (Fig. 4B).
Taken together, the pan-caspase-inhibitors, Z-
VAD.fmk and Q-VD-OPh, were able to almost
completely block MNNG-induced toxicity, and West-
ern blot analysis revealed a PARP-1-cleavage product
as well as caspase-7 and caspase-9 activation. These
data together with the results of the ADP/ATP assay
indicate that low doses of the alkylating agentMNNG
induced a caspase-dependent apoptotic cell death.
The role of PARP-1, PARP-2 and PARG in MNNG-
induced AIF translocation. Cell death triggered by
PAR may be mediated by AIF [19, 20], a mitochon-
drial flavoprotein that translocates to the nucleus. We
determined which of the PAR-metabolizing enzymes
contribute to the synthesis of PAR triggering AIF
translocation. PARP-1, PARP-2 and PARG were
silenced either singly or in combination and HeLa
cells were challenged with 50 mMMNNG. AIF trans-
location was monitored by immunofluorescence
(Fig. 5A). MNNG treatment caused AIF transloca-
tion into the nucleus in 57%of cells (Fig. 5A), and this
was reduced to 33% in PARP-1-silenced cells
(Fig. 5A). In addition, we isolated mitochondria and
nuclei and determined AIF distribution in these two
fractions by Western blot analysis (Fig. 5B), using
manganese superoxide dismutase (MnSOD) and
topoACHTUNGTRENNUNGisomerase I as mitochondrial and nuclear marker
proteins, respectively. Neither of the PARPs nor
PARG silencing per se had an effect on the local-
ization of AIF. However, PARP-1 silencing strongly
inhibited AIF translocation from mitochondria to the
nucleus following MNNG-treatment of HeLa cells.
Similar findings were observed in cells where PARP-1
and PARP-2 were simultaneously down-regulated,
whereas PARP-2 or PARG silencing did not effect the
translocation ofAIF (Fig. 5B). To assess possible cross
contamination,mitochondrial and nuclear fractions of
three independent experiments were analyzed by
immunoblot analyses concurrently with antibodies
specific for MnSOD and Topo-I (Fig. S4). Generally,
the amounts of cross contamination within the frac-
tionation experiments differed slightly, explaining the
rather strong signal of AIF in the nuclei of control and
PARG-down-regulated cells in the absence ofMNNG
in comparison to the signal of AIF in the nuclei of
untreated control as well as PARP-1-, PARP-2- and
PARP-1/PARP-2-silenced cells (Fig. 5B). Quantifica-
tion of Western-blot analysis confirmed AIF trans-
location after MNNG treatment in control as well as
PARP-2- and PARG-down-regulated cells, whereas
AIF translocation was inhibited after PARP-1-down-
regulation and the double silencing of PARP-1 and
PARP-2.
Figure 4. Low doses of the DNA alkylating agentMNNG induced
caspase-dependent apoptotic cell death. (A) Exponentially grow-
ing HeLa cells were treated with MNNG (50 mM) in absence or
presence of the broad-spectrum caspase-inhibitors Z-VAD.fmk
(100 mM) and Q-VD-OPh (20 mM). After 20 h cells were analyzed
byAlamar Blue assay to determine the cell viability as described in
Materials andmethods. Cell viabilitieswere expressed as percent of
untreated control cells. Results represent the means  SD for at
least six determinations (* p<0.0001, unpaired t-test). (B) Western
blot analysis of cleaved caspase-7 and -9 in the absence or presence
of the caspase-inhibitor Q-VD-OPh. HeLa cells were treated for
20 h with MNNG (50 mM) in absence or presence of the broad-
spectrum caspase-inhibitor Q-VD-OPh (20 mM). Immunoblotting
of whole cell lysates was performed with antibodies detecting
activated caspase-7 and -9. (C) Western blot analysis of caspase-
dependent cleavage of PARP-1 as well as activated caspase-7 and
caspase-9 after MNNG-induced cell death. Cells transfected with
siRNA were treated with 50 mM MNNG for 20 h as indicated.
Immunoblotting of whole cell lysates was performed with anti-
bodies detecting the full-length form and the 85-kDa fragment of
PARP-1 as well as cleaved caspase-7 and caspase-9. The blots were
exposed longer than those of Fig. 1A to visualize potentially low
amounts of cleavage fragments.
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Discussion
In an elegant series of studies, Dawson and collabo-
rators [20, 21] elucidated PAR as a cell death signal. In
particular, PAR was found to mediate between DNA
damage and the translocation of AIF from mitochon-
dria to the nucleus. Another study focusing on
MNNG-induced cell death andAIFrelease, suggested
sequential activation of PARP-1, calpains, Bax and
AIF in a single cell death pathway [32]. All of these
studies were performed with high doses of MNNG
(500 mM) inducing a caspase-independent necrotic
form of programmed cell death.
In the present study, we chose a low dose (50 mM)
MNNG treatment that triggers apoptotic cell death.
This type of cell death involves moderate activation of
PAR synthesis, moderate changes in the ADP/ATP
ratio of cells, activation of caspases-7 and -9, proteo-
lytic processing of PARP-1, and AIF translocation
from mitochondria to the nucleus. No changes were
observed in the expression of Topo-I, p53, PCNA, bcl-
2, and bax (Fig. S3).
Dissecting the contribution of several PAR-metabo-
lizing enzymes by RNAi in living cells, we observed
that only PARP-1, and not PARP-2 and PARG, are
involved in this type of cell death. Surprisingly,
PARG-silencing did not affect the translocation of
AIFand consequently had no impact on the cell death
response of these cells, although it caused quite drastic
changes in the pattern of PARs synthesized. Naturally,
the absence of a PARG- and PARP-2-silencing effect
may be attributable to residual molecules. In the case
of PARG, there are about 50 000 molecules in
mammalian cells [14, 33], and following the 90%
silencing achieved with the present protocol, about
5000 PARG molecules would escape down-regula-
tion. In addition ADP-ribose-(arginine) protein hy-
drolase 3 (AHR3) catalyzes an alternative enzymatic
activity for the degradation of poly(ADP-ribose) and
must therefore be taken into account for residual PAR
degradation activity within PARG-silenced cells [34].
However, at this level, we see a dramatic accumula-
tion of PAR molecules (Fig. 2, [30]), suggesting that
silencing is sufficient to visibly reduce PAR catabo-
lism, and this is sufficient to provide a substantial
protection of both human and murine cells against
oxidant-induced apoptosis ([30], unpublished data).
Thus, it seems that the type of PARmolecules relevant
forMNNG-induced cell death is primarily determined
by PARP-1. Likewise, PARP-1 seems to participate in
the events affecting the ADP/ATP ratio and AIF
translocation from mitochondria to nuclei, but not in
the activation of caspases-7 or -9.
In contrast to recently published data showing that
MNNG-mediated necrosis proceeds in a caspase-
independent manner [32], we observed that PAR
polymer-induced cell death in HeLa cells after low
doses of MNNG treatment could be prevented by
caspase inhibition. In addition, we observed caspase
cleavage of PARP-1 as well as caspases-7 and -9
activation, in combination with the results of the
ADP/ATP-ratio assay, further corroborating an apop-
totic form of cell death after low doses of MNNG.
Our results confirm the concept of an intrinsic cell
death pathway triggered by PAR [21, 35]. The
polymer pattern obtained with low doses of MNNG
(up to 35 ADP-ribose units) was capable of triggering
AIF release and apoptosis. This finding was in agree-
ment with recent studies showing that an 80 nM of 16-
unit polymers already cause a moderate AIF release,
whereas 80 nMof 30-unit polymers induces significant
and 80 nM of more than 60-unit polymers (or mixed
polymers) a robustAIF release [20].How the polymer
branching impacts on these parameters is not known
at present. However, in general, branching increases
with PAR size [36, 37]. We identified PARP-1 as the
major configurator of PAR as a cell death signal, while
Figure 5. Influence of PARP-1, PARP-2 and PARG knockdown
on the translocation of apoptosis-inducing factor (AIF) after
MNNG- induced cell death. (A) Immunofluorescence analysis of
AIF in HeLa cells transfected with control or PARP-1-specific
siRNA after 6 h of MNNG treatment. (B) Analysis of AIF
translocation by subcellular fractions. SiRNA-transfected cells
(as indicated) treated with MNNG (50 mM) were subjected to
subcellular fractionation and immunoblotting as described in
Material and methods. (C) Analysis of the mitochondrial to
nuclear AIF ratio as described under Materials and methods. The
ratios indicate the value of mitochondrial AIF over nuclear AIF
relative to siRNA-C transfected untreated control cells.
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PARP-2 and PARG had no measurable influence
under the silencing conditions shown. In agreement
with recent reports [19, 20, 32], PAR induces AIF
release, which then translocates frommitochondria to
the nucleus, leading to nuclear condensation and
programmed cell death. Moreover, whether high-
dose-MNNG-mediated necrotic cell death is induced
[20, 32] orwhether apoptotic cell death by lowdoses of
the alkylating agent was analyzed, this did not change
the death link between PARP-1 and mitochondrial
AIF release. Thus, the PARP-1-generated death signal
operates in both death pathways, although the path-
ways differ in substantial intermediary steps, such as
the involvement of caspases.
An unanswered question is the potential role of
NAD+ depletion in PARP-1-mediated AIF release
and cell death. Swanson and co-workers [38] suggest-
ed that both NAD+ depletion and mitochondrial
permeability transition are necessary in the cell death
program leading from PARP-1 activation to AIF
release and cell death in an astrocyte model using
100 mM MNNG. These aspects as well as the evolu-
tionary relationship of the PARP-1 signal relative to
these pathways are now subject of further studies.
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